KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Buildings (2023 - 2025)

Edwards Lifesciences has reported Buildings over the past 3 years, most recently at $1.4 billion for Q4 2025.

  • For Q4 2025, Buildings rose 3.99% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 3.99%, while the annual FY2025 figure was $1.4 billion, 3.99% up from the prior year.
  • Buildings for Q4 2025 was $1.4 billion at Edwards Lifesciences, up from $1.3 billion in the prior quarter.
  • Over five years, Buildings peaked at $1.4 billion in Q4 2025 and troughed at $1.2 billion in Q4 2023.
  • A 3-year average of $1.3 billion and a median of $1.3 billion in 2024 define the central range for Buildings.
  • Biggest five-year swings in Buildings: increased 12.68% in 2024 and later rose 3.99% in 2025.
  • Year by year, Buildings stood at $1.2 billion in 2023, then grew by 12.68% to $1.3 billion in 2024, then increased by 3.99% to $1.4 billion in 2025.
  • Business Quant data shows Buildings for EW at $1.4 billion in Q4 2025, $1.3 billion in Q4 2024, and $1.2 billion in Q4 2023.